TCGA-97-A4M7-01A-11R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.350
- ALLOGRAFT_REJECTION+0.310
- KRAS_SIGNALING_DN+0.300
- COAGULATION+0.290
- INTERFERON_GAMMA_RESPONSE+0.290
- ANGIOGENESIS+0.280
- MYOGENESIS+0.280
- KRAS_SIGNALING_UP+0.260
- INFLAMMATORY_RESPONSE+0.220
- HEDGEHOG_SIGNALING+0.210
Top 10 suppressed
- MYC_TARGETS_V1-0.710
- MYC_TARGETS_V2-0.690
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.610
- OXIDATIVE_PHOSPHORYLATION-0.590
- MTORC1_SIGNALING-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.460
- DNA_REPAIR-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ANDROGEN_RESPONSE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-A4P7-01A-11R-A24X-07 | — | cohortA1 | 0.938 |
| 2 | BS_0XEG6SNV | EPN | Supratentorial EPN | 0.921 |
| 3 | TCGA-S2-AA1A-01A-12R-A39D-07 | — | cohortA1 | 0.921 |
| 4 | SRR6013478 | — | cohortMD2 | 0.918 |
| 5 | TCGA-55-8510-01A-11R-2403-07 | — | cohortA1 | 0.916 |
| 6 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.916 |
| 7 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.914 |
| 8 | BS_GTZCFGRZ | Ganglioglioma | — | 0.913 |
| 9 | SRR26320079 | — | — | 0.912 |
| 10 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |